Originally published In Press as doi:10.1074/jbc.M108023200 on March 19, 2002
J. Biol. Chem., Vol. 277, Issue 22, 19546-19553, May 31, 2002
Phloxine B Interacts with the Cystic Fibrosis Transmembrane
Conductance Regulator at Multiple Sites to Modulate Channel
Activity*,
Zhiwei
Cai and
David N.
Sheppard
From the Department of Physiology, University of Bristol, School of
Medical Sciences, University Walk, Bristol BS8 1TD and the Medical
Genetics Section, University of Edinburgh, Molecular Medicine Centre,
Western General Hospital, Edinburgh EH4 2XU, United Kingdom
Received for publication, August 20, 2001, and in revised form, February 19, 2002
 |
ABSTRACT |
The fluorescein derivative phloxine B is a potent
modulator of the cystic fibrosis transmembrane conductance regulator
(CFTR). Low micromolar concentrations of phloxine B stimulate CFTR
Cl
currents, whereas higher concentrations of the
drug inhibit CFTR. In this study, we investigated the mechanism of
action of phloxine B. Phloxine B (1 µM) stimulated
wild-type CFTR and the most common cystic fibrosis mutation,
F508,
by increasing the open probability of phosphorylated CFTR
Cl
channels. At each concentration of ATP tested, the
drug slowed the rate of channel closure without altering the opening
rate. Based on the effects of fluorescein derivatives on transport
ATPases, these data suggest that phloxine B might stimulate CFTR by
binding to the ATP-binding site of the second nucleotide-binding
domain (NBD2) to slow the dissociation of ATP from NBD1. Channel block by phloxine B (40 µM) was voltage-dependent,
enhanced when external Cl
concentration was reduced and
unaffected by ATP (5 mM), suggesting that phloxine B
inhibits CFTR by occluding the pore. We conclude that phloxine B
interacts directly with CFTR at multiple sites to modulate channel
activity. It or related agents might be of value in the development of
new treatments for diseases caused by the malfunction of
CFTR.
 |
INTRODUCTION |
The cystic fibrosis transmembrane conductance regulator
(CFTR1 (1)) is a novel member
of the ATP-binding cassette (ABC) transporter family that forms a
Cl
channel with complex regulation (2, 3). It is
predominantly expressed in epithelia, where it provides a pathway for
the movement of Cl
ions across the apical membrane and
regulates the rate of transepithelial salt and water transport (4).
Dysfunction of CFTR is associated with a wide spectrum of disease. The
genetic disease cystic fibrosis (CF) is caused by loss of function of
the CFTR Cl
channel (4). CF affects ~1 in 2500 live
births and is the most common fatal autosomal recessive disease to
affect Caucasian populations (4). Other diseases, such as autosomal
dominant polycystic kidney disease (ADPKD) and secretory diarrhea,
likely involve increased activity of the CFTR Cl
channel
(5, 6). ADPKD affects more than 1 in 1000 live births and is the most
common single gene defect associated with the loss of kidney function
(5). Secretory diarrhea annually kills millions of infants in Africa,
Asia, and Latin America (7). The prevalence of these diseases suggests
that modulators of the CFTR Cl
channel have significant
therapeutic potential.
Several pharmacological strategies to manipulate the activity of the
CFTR Cl
channel have been identified. Some agents promote
channel opening by modulating the activity of the protein kinases and
phosphatases that regulate CFTR (2, 8). For example, the
phenylimidazothiazole drug bromotetramisole inhibits the protein
phosphatases that dephosphorylate CFTR (9). In contrast, other agents
interact directly with CFTR to enhance channel activity (8, 10). The
binding of the flavonoid genistein to the second nucleotide-binding
domain (NBD2) prolongs dramatically the duration of channel openings (11-14), whereas cyclophilin A, a cis-trans peptidyl-prolyl
isomerase, interacts with the R (regulatory) domain to stimulate
greatly the activity of CFTR (15).
New inhibitors of the CFTR Cl
channel have emerged from
studies of agents that interact with other ABC transporters, including the sulfonylurea receptor (SUR) and multidrug-resistance associated proteins (MRPs, Ref. 16). SUR is the regulatory subunit of
ATP-sensitive K+ channels (KATP channels (17)).
It binds sulfonylureas, a class of hypoglycemia-inducing drugs used to
treat non-insulin-dependent diabetes mellitus, to inhibit
K+ flow through the pore-forming subunit of
KATP channels (Kir6.2 (17)). Like their effects on
KATP channels, the sulfonylureas glibenclamide and
tolbutamide and the non-sulfonylurea hypoglycemic agents meglitinide
and mitiglinde inhibit the CFTR Cl
channel (18-20). MRPs
hydrolyze ATP to export a wide range of large anions from cells (21).
Linsdell and Hanrahan (22) demonstrated that two substrates of MRPs,
taurolithocholate-3-sulfate and
-estradiol 17-(
-D-glucuronide), inhibit the CFTR Cl
channel. The data indicate that hypoglycemia-inducing drugs and substrates of MRPs block the CFTR Cl
channel by occluding
the intracellular end of the CFTR pore (19, 22).
In the search for new modulators of CFTR, we tested the effect on the
CFTR Cl
channel of fluorescein derivatives, a group of
drugs used to investigate the function of transport ATPases and
KATP channels (23-26). Like its effect on KATP
channels (25), the fluorescein derivative phloxine B both stimulated
and inhibited channel activity (27, present study). To understand
better the mechanism of action of phloxine B, we studied CFTR
Cl
channels in excised inside-out membrane patches from
cells expressing human CFTR.
 |
EXPERIMENTAL PROCEDURES |
Cells and Cell Culture--
For these studies, we used mouse
mammary epithelial cells (C127 cells) stably expressing either
wild-type human CFTR or
F508, the most common CF-associated mutation
(28). C127 cells expressing wild-type CFTR were cultured as previously
described (19). C127 cells expressing
F508 CFTR were cultured at
28 °C to overcome the processing defect of this mutation and promote
its delivery to the cell membrane (29). Cells were seeded onto glass
coverslips and used within either 2 days (wild-type CFTR) or 1 week
(
F508 CFTR).
Electrophysiology--
CFTR Cl
channels were
recorded in excised inside-out membrane patches using an Axopatch 200A
patch-clamp amplifier (Axon Instruments Inc., Union City, CA) and
pClamp data acquisition and analysis software (version 6.03, Axon
Instruments Inc.) as previously described (19, 30). The established
sign convention was used throughout; currents produced by positive
charge moving from intra- to extracellular solutions (anions moving in
the opposite direction) are shown as positive currents.
The pipette (extracellular) solution contained (in millimolar): 140 N-methyl-D-glucamine (NMDG), 140 aspartic acid,
5 CaCl2, 2 MgSO4, and 10 N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid
(TES), pH 7.3, with Tris ([Cl
], 10 mM). The
bath (intracellular) solution contained (millimolar): 140 NMDG, 3 MgCl2, 1 CsEGTA, and 10 TES, pH 7.3, with HCl
([Cl
], 147 mM, free [Ca2+],
<10
8 M) and was maintained at 37 °C.
After excision of inside-out membrane patches, CFTR Cl
channels were activated by the addition of the catalytic subunit of protein kinase A (PKA, 75 nM) and ATP (1 mM) to
the intracellular solution within 5 min of patch excision. Unless
otherwise specified, the ATP concentration was reduced to 0.3 mM before the addition of phloxine B to the intracellular
solution as previously described (31); PKA was added to all
intracellular solutions. Membrane patches were voltage-clamped at
50 mV.
In this study, we used membrane patches containing large numbers of
active channels for time-course studies and voltage ramp protocols and
membrane patches containing five or less active channels for
single-channel studies. The number of channels in a membrane patch was
determined from the maximum number of simultaneous channel openings
observed during the course of an experiment as described previously
(32). Because the effects of phloxine B on CFTR Cl
channels were only partially reversible (Fig. 7C), specific
interventions were not bracketed by control periods. However, we have
previously shown that in the continuous presence of PKA and ATP rundown
of CFTR Cl
channels in excised membrane patches from C127
cells is minimal (19).
To investigate whether phloxine B inhibition of CFTR was
voltage-dependent and enhanced when the external
Cl
concentration was reduced, we used voltage ramp
protocols to acquire macroscopic current-voltage
(I-V) relationships as previously described
(31). Basal currents recorded before the addition of PKA and ATP were
subtracted from those recorded in the absence and presence of phloxine
B to determine the effect of phloxine B on CFTR Cl
currents.
CFTR Cl
currents were initially recorded on digital
audiotape using a digital tape recorder (Biologic Scientific
Instruments, model DTR-1204, Intracel Ltd., Royston, UK) at a bandwidth
of 10 kHz. On playback, records were filtered with an eight-pole Bessel
filter (Frequency Devices, model 902LPF2, Scensys Ltd., Aylesbury, UK)
at a corner frequency of 500 Hz and acquired using a Digidata 1200 interface (Axon Instruments, Inc.) and pClamp at sampling rates of
either 2.5 kHz (time-course studies) or 5 kHz (single-channel studies).
For the purpose of illustration, single-channel records were filtered
at 500 Hz and digitized at 1 kHz.
In time-course studies, each data point is the average current for a
4-s period with data points collected continuously; no data were
collected while solutions were changed. Average current (I) for a
specific intervention was determined as the average of all the data
points collected during the intervention. The relationship between drug
concentration and CFTR inhibition was fitted to the Hill equation,
|
(Eq. 1)
|
where [Drug] is the concentration of drug,
IDrug/IControl is the
fractional current at the indicated drug concentration relative to that
in the same solution in the absence of added drug,
Ki is the drug concentration causing half-maximal
inhibition, and n is the slope factor (Hill coefficient).
Mean data were fitted to a linear form of Equation 1 using linear
least-squares regression to yield Ki and
n values.
To measure single-channel current amplitude (i), Gaussian distributions
were fit to current amplitude histograms. For open probability
(Po) and burst analyses, lists of open- and
closed-times were created and analyzed as previously described (31).
Burst analysis was performed as described by Carson et al.
(33), using a tc (the time that separates
interburst closures from intraburst closures) of 15 ms. Mean interburst
interval (Tc) was calculated using the
equation,
|
(Eq. 2)
|
where Tb = (mean burst duration) × (open probability within a burst). Mean burst duration and open
probability within a burst were determined directly from experimental
data; Po was calculated from open and closed
times. Only membrane patches that contained a single active channel
were used for burst analysis.
To perform maximum likelihood analysis and develop kinetic models to
quantify the interaction of phloxine B with CFTR, we used the QuB
software suite (www.qub.buffalo.edu). In brief, digitized current
records generated by pClamp software were imported with no further
filtering and baseline corrected (program PRE). Using a recursive
Viterbi algorithm (program SKM), idealized currents were produced.
Finally, rate constants for kinetic models were calculated from the
idealized current dwell time sequence using a maximum likelihood
approach (program MIL). For consistency with analyses using pClamp
software, transitions of <1 ms were excluded. With the exception of
the ADP data (Fig. 5 and supplementary information), only membrane
patches that contained a single active channel were used for maximum
likelihood analysis and kinetic modeling.
Reagents--
PKA was purchased from Promega Corp. (Southampton,
UK). ATP (disodium salt), glibenclamide, phloxine B
(2',4',5',7'-tetrabromo-4,5,6,7-tetrachlorofluorescein, Fig.
1A), and TES were obtained from the Sigma-Aldrich Company Ltd. (Gillingham, UK). All other chemicals were of reagent grade.
Stock solutions of phloxine B were prepared in Me2SO
and stored at
20 °C. Immediately before use, stock solutions were
diluted to achieve final concentrations. Me2SO did not
affect the activity of CFTR (19).
Statistics--
Results are expressed as means ± S.E. of
n observations. To compare sets of data, we used Student's
t test. Differences were considered statistically
significant when p < 0.05.
 |
RESULTS |
Phloxine B Stimulates and Inhibits the Activity of CFTR--
To
examine the effect of the fluorescein derivative phloxine B on the
activity of CFTR, we studied CFTR Cl
currents in excised
inside-out membrane patches from C127 cells expressing wild-type human
CFTR. In the absence of either ATP (n = 4) or PKA
(n = 4), phloxine B was without effect on CFTR Cl
channels (data not shown). However, in the presence of
both PKA (75 nM) and ATP (0.3 mM), addition of
phloxine B to the intracellular solution altered channel activity (Fig.
1, B and C).
Phloxine B (0.1-5 µM) stimulated CFTR Cl
current whereas, phloxine B (20-50 µM) inhibited channel
activity. The inset of Fig. 1C shows the fit of the Hill
equation to the relationship between phloxine B concentration and
current inhibition (Ki = 17 µM;
n = 2; correlation coefficient,
r2 = 0.943 at
50 mV). These data suggest that
phloxine B is a potent modulator of the CFTR Cl
channel:
it stimulates CFTR with greater efficacy than genistein, and it
inhibits channel activity with equipotency to glibenclamide (13, 19).
The Hill plot also suggests that phloxine B might inhibit CFTR by
binding at two or more sites that interact co-operatively. Modulation
of CFTR by phloxine B was partially reversible (see Fig. 7C,
below).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 1.
Phloxine B modulates the activity of
CFTR. A, chemical structure of phloxine B. The anionic
form is shown. B, time course of CFTR Cl
current in an excised inside-out membrane patch. ATP (0.3 mM), PKA (75 nM), and phloxine B (Phlx
B, 5-50 µM) were present in the intracellular
solution during the times indicated by the bars. Unless
otherwise indicated, in this and subsequent figures, voltage was 50
mV and there was a Cl concentration gradient across the
membrane (internal [Cl ] = 147 mM; external
[Cl ] = 10 mM). For the purpose of
illustration, the time course has been inverted so that upward
deflections represent inward currents. C, effect of phloxine
B concentration on CFTR Cl currents. Data are means ± S.E. (n = 4-7). Values above the dotted
line indicate stimulation of CFTR, whereas values below the
line indicate inhibition. Other details are as in B.
The inset shows a Hill plot of phloxine B inhibition of
CFTR. The continuous line is the fit of a first-order
regression to the data.
|
|
Mechanism of Phloxine B Stimulation of CFTR--
In principle,
phloxine B might stimulate CFTR Cl
currents in one of
three ways: first, by increasing the number of active channels; second,
by enhancing current flow through open channels; third, by increasing
Po. To discriminate between these different possibilities, we investigated the effect of phloxine B (1 µM) on the single-channel activity of CFTR (Fig.
2). Visual inspection of single-channel
records suggests that phloxine B (1 µM) did not stimulate
CFTR by enhancing the number of active channels present in a membrane
patch (n = 15, Fig. 2A). Similarly, phloxine B (1 µM) did not stimulate CFTR by increasing the amount
of current flowing through an open channel. On the contrary, the drug
produced a small, but significant (p < 0.05),
reduction in i (Fig. 2B). Instead, phloxine B (1 µM) caused a large increase in Po
(p < 0.0001; Fig. 2C).

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 2.
Phloxine B (1 µM) stimulates the single-channel
activity of CFTR. A, representative recordings show the
effect of phloxine B (1 µM) on the activity of a single
CFTR Cl channel in an excised inside-out membrane patch.
ATP (0.3 mM) and PKA (75 nM) were continuously
present in the intracellular solution. Dashed lines indicate
the closed channel state and downward deflections correspond to channel
openings. B and C, effect of phloxine B (1 µM) on i and Po,
respectively. Columns and error bars indicate
means + S.E. (n = 15). The asterisks
indicate values that are significantly different from the control value
(p < 0.01); other details are as in
A.
|
|
To determine how phloxine B (1 µM) increased
Po, we investigated its effects on the gating
kinetics of phosphorylated CFTR Cl
channels using
membrane patches that contained only a single active channel. Using
maximum likelihood analysis, Winter et al. (34) demonstrated
that the simplest model to describe the gating kinetics of single
phosphorylated wild-type CFTR Cl
channels is a linear
three-state model (Fig. 3A).
In this model, C1 represents the long duration
closed state separating bursts of channel activity and
C2
O represents the bursting
state in which channel openings (O) are interrupted by brief
flickery closures (C2). Transitions between the
three states are described by the rate constants
1,
2,
1, and
2. Winter
et al. (34) demonstrated that intracellular ATP regulates
CFTR at the transition between C1 and
C2: as the ATP concentration increases,
1 increases. In contrast, the other transitions were not
altered significantly by ATP (34). Similar analyses of our data support
this model of ATP-dependent regulation of CFTR channel
gating (see supplementary material).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of phloxine B (1 µM) on single-channel kinetics.
A, a linear three-state model which describes the gating
behavior of phosphorylated wild-type CFTR Cl channels
(34). States C1, C2, and
O represent two closed states and one open state,
respectively, while 1, 2,
1, and 2 represent the rate constants
describing transitions between the open and closed states.
B, effect of phloxine B (1 µM) on the rate
constants determined by the maximum likelihood fit to the model shown
in A. Data are from six single-channel patches. The
asterisks indicate values that are significantly different
from the control value (p < 0.01); other details are
as in Fig. 2A.
|
|
Fig. 3B summarizes the effect of phloxine B (1 µM) on the rate constants. The major effect of phloxine B
(1 µM) was to decrease
1 to about 40% of
the control value. The drug also increased
2 but did not
change either
1 or
2. The decrease in
1 delays the exit from the bursting state to the
long-lived closed state and, hence, increases burst duration. The
increase in
2, the transition rate between the
short-lived closed state and the open state, further increases the
duration of bursts. These changes explain the observed increase in
Po caused by phloxine B (1 µM, Fig. 2C).
Effect of ATP and ADP on Phloxine B Stimulation of CFTR--
The
effect of phloxine B (1 µM) on channel gating resembles
that of adenosine 5'-(
,
-imino)triphosphate (AMP-PNP) and
genistein, two activators of the CFTR Cl
channel.
Previous work suggests that these agents interact directly with NBD2,
which regulates channel closure (11-14, 35). Based on these data and
the observation that fluorescein derivatives prevent the hydrolysis of
ATP by transport ATPases (23, 24), we speculated that phloxine B might
compete with ATP for a common binding site on NBD2. To test this
hypothesis, we examined the effect of ATP concentration on phloxine B
(1 µM) stimulation of CFTR Cl
channels.
Fig. 4 (A and B)
shows that, as the ATP concentration increased, CFTR activity in both
the absence and presence of phloxine B (1 µM) increased.
With the exception of ATP (3 mM), at each concentration of
ATP tested, Po values in the presence of
phloxine B (1 µM) were significantly greater than those
recorded in the absence of the drug (p < 0.05; Fig.
4B). In both the absence and presence of phloxine B (1 µM), mean data were best fitted by a Michaelis-Menten
function (control: Km = 197 µM,
maximum Po (Po max) = 0.59, r2 = 0.963; phloxine B:
Km = 33 µM,
Po max = 0.73; r2 = 0.983). These data suggest that phloxine B (1 µM)
increases the affinity of CFTR for ATP. They also raise the possibility that phloxine B might not compete with ATP for a common binding site.

View larger version (54K):
[in this window]
[in a new window]
|
Fig. 4.
Phloxine B (1 µM) enhances ATP-dependent
stimulation of CFTR. A, representative recordings show
the effect of phloxine B (1 µM) on the activity of a
single CFTR Cl channel in the presence of different ATP
concentrations. B, relationship between ATP concentration
and Po in the absence (filled
circles) and presence (open circles) of phloxine B (1 µM). Symbols and error bars are
means ± S.E. (n = 6-12, except 3 mM
ATP where n = 3) of paired data at each dose.
Continuous lines are Michaelis-Menten fits to the mean data.
C and D, relationship between ATP concentration
and mean burst duration and interburst interval, respectively, in the
absence (filled circles) and presence (open
circles) of phloxine B (1 µM). Symbols
and error bars are means ± S.E. (n = 3-7). Other details are as in Fig. 2A.
|
|
To quantify the effect of phloxine B (1 µM) on channel
gating in the presence of different concentrations of ATP, we performed an analysis of bursts using a burst delimiter
(tc) of 15 ms.2 Under control
conditions, both interburst interval and burst duration exhibited ATP
dependence. Interburst interval was highly ATP-dependent,
decreasing 11-fold between 0.03 and 5 mM ATP (Fig. 4D). In contrast, burst duration was weakly
ATP-dependent at low ATP concentrations, increasing
1.4-fold between 0.03 and 1 mM ATP, but ATP-independent at
higher ATP concentrations (Fig. 4C). Phloxine B (1 µM) was without effect on the ATP dependence of the
interburst interval (Fig. 4D). However, the drug caused a marked increase in burst duration at each concentration of ATP tested
(Fig. 4C). These data correlate well with the results of maximum likelihood analysis of phloxine B (1 µM)
stimulation of CFTR (Fig. 3 and supplementary material).
Winter et al. (34) demonstrated that ADP inhibits CFTR by
slowing dramatically the rate of channel opening. To test the effect of
phloxine B (1 µM) on ADP inhibition of CFTR, we first added ADP (0.3 mM) and then phloxine B (1 µM)
to the intracellular solution in the continuous presence of ATP (0.3 mM) and PKA (75 nM, Fig.
5). Fig. 5 (A and
B) shows that phloxine B (1 µM) stimulated CFTR Cl
channels inhibited by ADP. To understand better
this effect, we studied the gating kinetics of CFTR using the
C1
C2
O model (Fig. 5, C and D). The major
effect of ADP (0.3 mM) was to decrease
1 to
about 40% of the control value (Fig. 5D). In contrast, in the presence of ADP (0.3 mM) and phloxine B (1 µM),
1 and
1 were decreased
to about 30% of the control values,
2 was increased to
about 140% of the control value, and
2 was unchanged
(Fig. 5D). These data indicate that ADP and phloxine B have
distinct effects on the gating kinetics of CFTR. The ADP-induced
decrease in
1 reduces the frequency with which CFTR
channels enter the bursting state, whereas all the changes in rate
constants produced by phloxine B prolong the duration of the bursting
state. Because the effects of ADP and phloxine B on the rate constants
oppose each other, Po in the presence of ADP and
phloxine B did not differ from that of the control (Fig.
5B).

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 5.
Phloxine B (1 µM) relieves ADP inhibition of
CFTR. A, representative recordings show the effect of
phloxine B (1 µM) on the activity of two CFTR
Cl channels inhibited by ADP (0. 3 mM).
B, effect of ADP (0.3 mM) and phloxine B (1 µM) on Po. Columns and
error bars indicate means + S.E. (n = 5).
The asterisk indicates a value that is significantly
different from the control value (p < 0.05).
C, a linear three-state model of CFTR channel gating (see
Fig. 3A and Ref. 34). D, effect of ADP (0.3 mM) and phloxine B (1 µM) on the rate
constants determined by the maximum likelihood fit to the model shown
in C. Data are from four patches containing between one and
four active channels. The asterisks indicate values that are
significantly different from the control value (p < 0.05); other details are as in Fig. 2A.
|
|
Mechanism of Phloxine B Inhibition of CFTR--
Previous studies
have demonstrated that some agents inhibit the CFTR Cl
channel by occluding the channel pore (19, 36, 37), whereas others
interfere with channel gating (13, 31, 34). To investigate how phloxine
B inhibits CFTR, we tested the effect of elevated concentrations of
phloxine B on the single-channel activity of CFTR (Fig.
6A). Visual inspection of
single-channel records suggests that phloxine B (20 µM)
altered channel gating in several ways. First, it greatly prolonged the
interburst interval (Fig. 6A). Second, it caused a large
increase in flickery closures interrupting bursts of channel activity
(Fig. 6A). Third, it appeared to prolong the duration of
bursts (Fig. 6A). To begin to quantify channel block, we
measured i and Po. Fig. 6
(B and C) demonstrates that phloxine B (20 µM) significantly decreased both i and
Po (p < 0.05).

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 6.
Elevated concentrations of phloxine B inhibit
CFTR Cl channels. A, representative
recordings show the effect of phloxine B (20 µM) on the
activity of three CFTR Cl channels. The 1-s portions of
trace indicated by the bars on the left are shown on an
expanded time scale to the right. B and
C, effect of phloxine B on i and
Po, respectively. Columns and
error bars indicate means + S.E. (n = 6).
The asterisks indicate values that are significantly
different from the control value (p < 0.05). Other
details are as in Fig. 2A.
|
|
Fluorescein derivatives inhibit glibenclamide binding to SUR (25, 26).
Based on these data, we were interested to learn the effect of phloxine
B on glibenclamide inhibition of CFTR. Stimulation of CFTR with
phloxine B (1 µM) failed to prevent channel block by
glibenclamide (50 µM, n = 5, data not
shown). Moreover, in the presence of glibenclamide (50 µM) and phloxine B (20 µM) channel
inhibition was greater than that observed in the presence of either
drug alone (p < 0.001, Fig.
7A and B (31)).
These data suggest that glibenclamide and phloxine B might interact
with CFTR at distinct sites.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 7.
Effect of glibenclamide and ATP on phloxine B
inhibition of CFTR. A, time-course of CFTR
Cl current in an excised inside-out membrane patch. ATP
(0.3 mM), PKA (75 nM), phloxine B (20 µM), and glibenclamide (Glib, 50 µM) were
present in the intracellular solution during the times indicated by the
filled bars. Other details as in Fig. 1B.
B, effect of glibenclamide (50 µM) on phloxine
B (20 µM) inhibition of CFTR Cl current.
Columns and error bars indicate means + S.E.
(n = 5). Values represent the average current recorded
during the indicated interventions normalized to that measured under
control conditions at the start of the experiment. Other details as in
A. C, time-course of CFTR Cl
current in an excised inside-out membrane patch. ATP (0.3 or 5 mM), PKA (75 nM), and phloxine B (20 µM) were present in the intracellular solution during the
times indicated by the filled bars. D, effect of
ATP concentration on phloxine B (20 µM) inhibition of
CFTR Cl currents. Columns and error
bars indicate means + S.E. (n = 6). Other details
are as in B and C.
|
|
Elevated concentrations of the CFTR activator genistein inhibit channel
activity by slowing greatly the rate of channel opening (13, 31). Like
genistein, phloxine B prolonged the duration of long closures
separating channel openings. This suggests that genistein and phloxine
B might inhibit the CFTR Cl
channel by similar
mechanisms. To test this idea, we investigated whether high
concentrations of ATP attenuate phloxine B inhibition of CFTR. In
contrast to genistein block of the CFTR Cl
channel (31),
ATP (5 mM) failed to relieve phloxine B (20 µM) inhibition of CFTR Cl
currents
(p > 0.05, Fig. 7, C and D).
The prolonged channel openings interrupted by flickery closures induced
by inhibitory concentrations of phloxine B (Fig. 6A) suggest
that phloxine B might be an open-channel blocker of CFTR. To
investigate this idea, we examined the voltage dependence of channel
inhibition. Membrane patches were bathed in symmetrical 147 mM Cl
solutions, and CFTR Cl
currents were recorded in the absence and presence of phloxine B (40 µM) over the voltage range ±100 mV using a voltage ramp protocol. Consistent with previous data (31), under control conditions,
CFTR Cl
currents exhibited weak inward rectification
(Fig. 8A). This rectification
of CFTR is caused by a reduction in i and changes in gating
behavior at voltages above +50 mV (38).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 8.
Phloxine B inhibition of CFTR is
voltage-dependent and enhanced when the external
Cl concentration is reduced. A,
I-V relationships of CFTR Cl currents
recorded in the absence and presence of phloxine B (40 µM) when the membrane patch was bathed in symmetrical 147 mM Cl solutions. ATP (1 mM) and
PKA (75 nM) were continuously present in the intracellular
solution; holding voltage was 50 mV. B, effect of voltage
on the fraction of CFTR Cl current inhibited by phloxine
B (40 µM). Values are means ± S.E.
(n = 5) at each voltage. The continuous line
is the fit of a second-order regression to the data. C,
relationship between the voltage-dependent dissociation
constant (Kd) and voltage when the external
Cl concentration was either 147 mM
(filled circles) or 10 mM (open
circles). Data are means ± S.E. (n = 4-5)
at each voltage. The continuous lines are the fits of
first-order regressions to the data.
|
|
Fig. 8A demonstrates that phloxine B inhibition of CFTR is
voltage-dependent. Phloxine B (40 µM)
decreased CFTR Cl
currents at negative voltages. However,
at positive voltages inhibition was relieved. Using current values
recorded in the presence and absence of phloxine B, we calculated the
voltage-dependent dissociation constant
(Kd) for phloxine B inhibition of CFTR from the
equation,
|
(Eq. 3)
|
where Kd(V) is the
voltage-dependent dissociation constant at voltage
V, and I and Io are the
current values in the presence and absence of drug, respectively. Fig.
8C demonstrates that Kd values showed
weak voltage dependence at negative voltages. However, at positive
voltages Kd values were strongly
voltage-dependent. The data also suggest that the potency of phloxine B inhibition of CFTR is comparable to glibenclamide and
greater than that of genistein (phloxine B, Kd(0 mV) = 49 ± 7 µM (n = 5);
glibenclamide, Kd(0 mV) = 37 ± 6 µM (19); genistein, Kd(0 mV) = 87 ± 11 µM (31)).
The electrical distance across the membrane sensed by blocking ions can
be calculated using the Woodhull relationship (39),
|
(Eq. 4)
|
where z' is the apparent valency of the
blocking ion (defined as the actual valency of the blocking ion
(z) multiplied by the electrical distance across the
membrane experienced by the blocking ion (
)), and F,
R, and T are the Faraday constant, gas constant,
and absolute temperature, respectively. Using the data in Fig.
8C, z' = 0.04 ± 0.01 (n = 5) measured from the inside of the membrane over the voltage range
100 to
40 mV.
Because phloxine B inhibition of CFTR was voltage-dependent
and unaffected by elevated ATP concentrations, we speculated that phloxine B might bind within the CFTR pore. To test this hypothesis, we
reduced the external Cl
concentration to 10 mM and recorded CFTR Cl
currents in the
absence and presence of phloxine B (40 µM) over the
voltage range
100 to 0 mV using a voltage ramp protocol. Fig.
8C demonstrates that reducing the external Cl
concentration enhances the potency of phloxine B inhibition of CFTR
(external [Cl
] = 147 mM,
Kd(0 mV) = 49 ± 7 µM
(n = 5); external [Cl
] = 10 mM, Kd(0 mV) = 26 ± 5 µM (n = 4); p < 0.05).
However, reducing the external Cl
concentration was
without effect on the electrical distance sensed by phloxine B
(z' = 0.06 ± 0.01 (n = 4) measured
from the inside of the membrane over the voltage range
100 to
40
mV; p > 0.05). Thus, these data indicate that phloxine
B inhibition of CFTR is voltage-dependent and enhanced when
the external Cl
concentration is reduced. This suggests
that phloxine B might inhibit CFTR by occluding the CFTR pore.
Phloxine B Stimulates the CF-associated Mutant
F508
CFTR--
To begin to evaluate the therapeutic potential of phloxine
B, we investigated whether phloxine B (1 µM) stimulates
the activity of
F508 CFTR, the most common CF-associated mutant.
F508 CFTR causes a loss of Cl
channel function in two
ways: first, it disrupts the biosynthesis of CFTR and second, it
perturbs channel gating (12, 40). To investigate whether phloxine B
stimulates the activity of
F508 CFTR Cl
channels, we
grew cells at 28 °C to overcome the defective processing of
F508
CFTR and facilitate its delivery to the cell membrane (29). Fig.
9A shows the effect of
phloxine B (1 µM) on the activity of a single
F508
CFTR Cl
channel following phosphorylation by PKA.
F508
CFTR Cl
channels are characterized by dramatically
prolonged closures separating bursts of channel openings. As a result,
the Po of
F508 CFTR is much less than that of
wild-type CFTR (Figs. 2 and 9). Phloxine B (1 µM)
increased the Po of
F508 CFTR 1.5-fold by
enhancing burst duration (p < 0.05) without altering
the interburst interval (p > 0.05, Fig. 9). These data
demonstrate that phloxine B (1 µM) stimulates
F508
CFTR Cl
channels.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 9.
Phloxine B (1 µM) stimulates the single-channel
activity of the CF-associated mutant
F508. A, representative recordings
show the effect of phloxine B (1 µM) on the activity of a
single F508 CFTR Cl channel. ATP (1 mM)
and PKA (75 nM) were continuously present in the
intracellular solution. B, C, and D,
effect of phloxine B (1 µM) on Po,
mean burst duration, and interburst interval. Columns and
error bars indicate means + S.E. (n = 3-5).
The asterisks indicate values that are significantly
different from the control value (p < 0.05). Other
details as in Fig. 2A.
|
|
 |
DISCUSSION |
The fluorescein derivative phloxine B is a potent modulator of
CFTR with complex effects on channel activity. Low micromolar concentrations of phloxine B stimulate CFTR by prolonging channel openings. In contrast, higher concentrations of the drug inhibit CFTR
by impeding Cl
permeation.
Activators of CFTR enhance channel activity either by regulating the
intracellular signaling pathways that control CFTR activity or
interacting directly with CFTR (8, 10). Several lines of evidence
suggest that phloxine B acts by the latter mechanism. First, PKA and
ATP were required for channel stimulation (27, present study). This
indicates that cAMP-dependent phosphorylation of CFTR is a
prerequisite for phloxine B to augment channel activity. Second,
phloxine B enhanced channel activity in excised inside-out membrane
patches (27, present study). This suggests that phloxine B might bind
directly to CFTR. Third, phloxine B stimulated channel activity by
prolonging the duration of channel openings (present study). Based on
previous work (for review see Ref. 2), this result suggests that
phloxine B might inhibit channel closure. These characteristics of
phloxine B stimulation of CFTR resemble those of genistein, a CFTR
activator that interacts directly with CFTR (11-14, 41). However, they
differ markedly from those of bromotetramisole, a CFTR activator that
inhibits protein phosphatases (9). Consistent with these data, phloxine
B (1 µM) and bromotetramisole (3 mM)
stimulation of CFTR Cl
currents was additive
(n = 4, data not shown).
Al-Nakkash et al. (42) proposed that genistein and
benzimidazolones stimulate CFTR by a common mechanism. These drugs
inhibit ATP hydrolysis at NBD2 to stabilize the open channel
configuration. Our observation that phloxine B inhibits channel closure
suggests that phloxine B might stimulate CFTR by a similar mechanism.
However, the observation that phloxine B, but not genistein, altered
the relationship between ATP concentration and channel activity (13, 27, 43, present study) argues that phloxine B stimulates CFTR by a
distinct mechanism. Given that fluorescein derivatives inhibit ATP
hydrolysis by transport ATPases (23, 24), that CFTR possesses two NBDs
that bind and hydrolysis ATP (44), and that phloxine B enhances the
affinity of CFTR for ATP (27, present study), we speculate that
phloxine B stimulates CFTR by interacting with the NBDs.
A variety of models have been proposed to account for the regulation of
channel gating by the NBDs (for discussion see Ref. 45). In the model
of Zeltwanger et al. (46), brief channel openings in the
presence of low ATP concentrations reflect ATP binding and hydrolysis
at NBD1, whereas prolonged channel openings in the presence of high ATP
concentrations reflect ATP binding and hydrolysis at NBD2. To explain
how phloxine B stimulates CFTR, we propose that phloxine B binding to
one NBD (we suggest NBD2) slows the rate of ATP dissociation at NBD1.
Consistent with our data, this interpretation predicts that phloxine B
would increase burst duration without altering the interburst interval.
Fluorescein derivatives interact with several sites on transport
ATPases, with the principal site being the high affinity ATP-binding
site of the catalytic subunit (23). These data suggest that phloxine B
might prevent ATP dissociation from NBD1 by binding at the ATP-binding
site of NBD2. This interpretation predicts that phloxine B and ATP
compete for a common binding site on NBD2. To test this idea, we used
phloxine (1 µM), whereas Bachmann et al. (27)
used phloxine B (300 nM). Because competition was only observed using phloxine B (300 nM (27)), phloxine B and ATP might only compete for a common binding site at non-saturating (nanomolar) concentrations of the drug. At saturating (micromolar) concentrations of the drug, phloxine B might interact with a site distinct from the ATP-binding site. Given that fluorescein derivatives are hydrophobic analogues of AMP (24) and AMP interacts with a site
distinct from that of ATP to enhance the affinity of NBD2 for ATP (14),
we speculate that high concentrations of phloxine B might stimulate
CFTR by binding at or near the AMP-binding site of NBD2.
Like genistein (13, 31), elevated concentrations of phloxine B inhibit
the CFTR Cl
channel. Both genistein and phloxine B caused
a flickery block that prolonged the duration of bursts and lengthened
dramatically the interburst interval (31, present study). However, ATP
(5 mM), voltage, and Cl
concentration had
markedly different effects on channel block by these agents (31, present study). Genistein inhibition was voltage-independent,
unaffected by reducing the external Cl
concentration, and
relieved by ATP (5 mM (31)). In contrast, phloxine B
inhibition was voltage-dependent, enhanced when the external Cl
concentration was reduced, and unaffected by
ATP (5 mM, present study). The failure of ATP (5 mM) to relieve phloxine B inhibition of CFTR was not a
consequence of the slow dissociation of the drug from the
channel.3
Previous work has demonstrated that large anions cause a
voltage-dependent block of the CFTR Cl
channel by binding to sites located 15-60% of the way through the
transmembrane electric field from the inside (19, 22, 36, 37, 47-49).
In contrast, the phloxine B-binding site is located only 4% of the way
through the transmembrane electric field from the inside. This suggests
that phloxine B interacts with a site outside the pore to block CFTR.
For two reasons, we do not favor this interpretation. First, phloxine B
inhibition of CFTR was voltage-dependent and enhanced when
the external Cl
concentration was reduced. These data
suggest strongly that phloxine B enters the CFTR pore from the
intracellular end, binds at or near Cl
-binding sites, and
blocks Cl
flow. Second, calculation of the electrical
distance that is sensed by phloxine B is complex. The Hill coefficient
for phloxine B inhibition of CFTR is 2. This suggests that phloxine B
might block the CFTR Cl
channel by binding to two or more
sites. Consistent with this idea, phloxine B possesses two negative
charges located on different parts of the molecule (Fig.
1A). This suggests that these charges might experience
different fractions of the transmembrane electric field when phloxine B
inhibits CFTR. However, the relationship between electrical distance
and physical distance within the CFTR pore is unknown. Based on our
experience with genistein (31), it is feasible that phloxine B might
bind to a site deep within the CFTR pore. Alternatively, the drug might
interact with a site at the extremity of the intracellular vestibule.
Given the location of the glibenclamide-binding site (19, 50) and our
observation that channel block by phloxine B and glibenclamide was
additive, we favor this possibility.
In conclusion, our data indicate that phloxine B is a potent modulator
of the CFTR Cl
channel. They also suggest that phloxine B
interacts directly with CFTR at multiple sites to modulate channel
activity. Based on the present results, future studies might identify
the phloxine B-binding sites.
 |
ACKNOWLEDGEMENTS |
We thank Professors D. C. Gadsby,
S. L. Flitsch, and M. J. Welsh and our departmental
colleagues for valuable discussions and Dr. C. R. O'Riordan (Genzyme) and Professor M. J. Welsh (University of
Iowa) for the generous gift of C127 cells.
 |
FOOTNOTES |
*
This work was supported by the Biotechnology and Biological
Sciences Research Council, Cystic Fibrosis Trust, and the National Kidney Research Fund.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The on-line version of this article (available at www.jbc.org)
contains Tables 1-3.
To whom correspondence should be addressed: Dept. of Physiology,
School of Medical Sciences, University of Bristol, University Walk,
Bristol BS8 1TD, United Kingdom. Tel.: 44-117-928-8992; Fax:
44-117-928-8923; E-mail: D.N.Sheppard@bristol.ac.uk.
Published, JBC Papers in Press, March 19, 2002, DOI 10.1074/jbc.M108023200
2
Similar results were observed using a
tc of 80 ms (n = 6).
3
We observed identical effects of ATP (5 mM) using eosin Y, a fluorescein derivative closely related
to phloxine B. Eosin Y and phloxine B stimulate and inhibit CFTR
Cl
currents with similar potency (n = 29, Z. Cai and D. N. Sheppard, unpublished observation).
However, channel block by eosin Y is readily reversible
(n = 5, data not shown) compared with that of phloxine B.
 |
ABBREVIATIONS |
The abbreviations used are:
CFTR, cystic fibrosis transmembrane conductance regulator;
CF, cystic
fibrosis;
ABC, ATP-binding cassette;
AMP-PNP, adenosine
5'-(
,
-imino)triphosphate;
ADPKD, autosomal dominant polycystic
kidney disease;
i, single-channel current amplitude;
I-V, current-voltage;
KATP channel, ATP-sensitive K+ channel;
MRP, multidrug-resistance
associated protein;
NBD, nucleotide-binding domain;
NMDG, N-methyl-D-glucamine;
PKA, protein kinase A;
Po, open probability;
R domain, regulatory
domain;
SUR, sulfonylurea receptor;
TES, N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic
acid.
 |
REFERENCES |
| 1.
|
Riordan, J. R.,
Rommens, J. M.,
Kerem, B.-S.,
Alon, N.,
Rozmahel, R.,
Grzelczak, Z.,
Zielenski, J.,
Lok, S.,
Plavsic, N.,
Chou, J.-L.,
Drumm, M. L.,
Iannuzzi, M. C.,
Collins, F. S.,
and Tsui, L.-C.
(1989)
Science
245,
1066-1073[Abstract/Free Full Text]
|
| 2.
|
Gadsby, D. C.,
and Nairn, A. C.
(1999)
Physiol. Rev.
79,
S77-S107[Medline]
[Order article via Infotrieve]
|
| 3.
|
Sheppard, D. N.,
and Welsh, M. J.
(1999)
Physiol. Rev.
79,
S23-S45[Medline]
[Order article via Infotrieve]
|
| 4.
|
Welsh, M. J.,
Tsui, L.-C.,
Boat, T. F.,
and Beaudet, A. L.
(1995)
in
The Metabolic and Molecular Basis of Inherited Disease
(Scriver, C. R.
, Beaudet, A. L.
, Sly, W. S.
, and Valle, D., eds)
, pp. 3799-3876, McGraw-Hill Inc., New York
|
| 5.
|
Sullivan, L. P.,
Wallace, D. P.,
and Grantham, J. J.
(1998)
Physiol. Rev.
78,
1165-1191[Abstract/Free Full Text]
|
| 6.
|
Gabriel, S. E.,
Brigman, K. N.,
Koller, B. H.,
Boucher, R. C.,
and Stutts, M. J.
(1994)
Science
266,
107-109[Abstract/Free Full Text]
|
| 7.
|
Guerrant, R. L.,
Hughes, J. M.,
Lima, N. L.,
and Crane, J.
(1990)
Rev. Infect. Dis.
12,
S41-S50[Medline]
[Order article via Infotrieve]
|
| 8.
|
Schultz, B. D.,
Singh, A. K.,
Devor, D. C.,
and Bridges, R. J.
(1999)
Physiol. Rev.
79,
S109-S144[Medline]
[Order article via Infotrieve]
|
| 9.
|
Luo, J.,
Zhu, T.,
Evagelidis, A.,
Pato, M. D.,
and Hanrahan, J. W.
(2000)
Am. J. Physiol.
279,
C108-C119
|
| 10.
|
Hwang, T.-C.,
and Sheppard, D. N.
(1999)
Trends Pharmacol. Sci.
20,
448-453[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
French, P. J.,
Bijman, J.,
Bot, A. G.,
Boomaars, W. E. M.,
Scholte, B. J.,
and de Jonge, H. R.
(1997)
Am. J. Physiol.
273,
C747-C753[Medline]
[Order article via Infotrieve]
|
| 12.
|
Hwang, T.-C.,
Wang, F.,
Yang, I. C.-H.,
and Reenstra, W. W.
(1997)
Am. J. Physiol.
273,
C988-C998[Medline]
[Order article via Infotrieve]
|
| 13.
|
Wang, F.,
Zeltwanger, S.,
Yang, I. C.-H.,
Nairn, A. C.,
and Hwang, T.-C.
(1998)
J. Gen. Physiol.
111,
477-490[Abstract/Free Full Text]
|
| 14.
|
Randak, C.,
Auerswald, E. A.,
Assfalg-Machleidt, I.,
Reenstra, W. W.,
and Machleidt, W.
(1999)
Biochem. J.
340,
227-235[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Xie, J.,
Zhao, J.,
Davis, P. B.,
and Ma, J.
(2000)
Biophys. J.
78,
1293-1305[Abstract/Free Full Text]
|
| 16.
|
Dean, M.,
Rzhetsky, A.,
and Allikmets, R.
(2001)
Genome Res.
11,
1156-1166[Abstract/Free Full Text]
|
| 17.
|
Inagaki, N.,
Gonoi, T.,
Clement IV, J. P.,
Namba, N.,
Inazawa, J.,
Gonzalez, G.,
Aguilar-Bryan, L.,
Seino, S.,
and Bryan, J.
(1995)
Science
270,
1166-1170[Abstract/Free Full Text]
|
| 18.
|
Venglarik, C. J.,
Schultz, B. D.,
DeRoos, A. D. G.,
Singh, A. K.,
and Bridges, R. J.
(1996)
Biophys. J.
70,
2696-2703[Abstract/Free Full Text]
|
| 19.
|
Sheppard, D. N.,
and Robinson, K. A.
(1997)
J. Physiol.
503,
333-346[Abstract/Free Full Text]
|
| 20.
|
Cai, Z.,
Lansdell, K. A.,
and Sheppard, D. N.
(1999)
Br. J. Pharmacol.
128,
108-118[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Oude Elferink, R. P. J.,
and Groen, A. K.
(2000)
Semin. Liver Dis.
20,
293-305[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Linsdell, P.,
and Hanrahan, J. W.
(1999)
Br. J. Pharmacol.
126,
1471-1477[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Karlish, S. J. D.
(1980)
J. Bioenerg. Biomembr.
12,
111-136[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Neslund, G. G.,
Miara, J. E.,
Kang, J.-J.,
and Dahms, A. S.
(1984)
Curr. Top. Cell Regul.
24,
447-469[Medline]
[Order article via Infotrieve]
|
| 25.
|
de Weille, J. R.,
Müller, M.,
and Lazdunski, M.
(1992)
J. Biol. Chem.
267,
4557-4563[Abstract/Free Full Text]
|
| 26.
|
Schwanstecher, M.,
Bachmann, C.,
Löser, S.,
and Panten, U.
(1995)
Pharmacology
50,
182-191[Medline]
[Order article via Infotrieve]
|
| 27.
|
Bachmann, A.,
Russ, U.,
Waldegger, S.,
and Quast, U.
(2000)
Br. J. Pharmacol.
131,
433-440[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Marshall, J.,
Fang, S.,
Ostedgaard, L. S.,
O'Riordan, C. R.,
Ferrara, D.,
Amara, J. F.,
Hoppe IV, H.,
Scheule, R. K.,
Welsh, M. J.,
Smith, A. E.,
and Cheng, S. H.
(1994)
J. Biol. Chem.
269,
2987-2995[Abstract/Free Full Text]
|
| 29.
|
Denning, G. M.,
Anderson, M. P.,
Amara, J. F.,
Marshall, J.,
Smith, A. E.,
and Welsh, M. J.
(1992)
Nature
358,
761-764[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Hamill, O. P.,
Marty, A.,
Neher, E.,
Sakmann, B.,
and Sigworth, F. J.
(1981)
Pflügers Arch.
391,
85-100[CrossRef][Medline]
|